HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pierre Hainaut Selected Research

N-(2-mercaptoethyl)-1,3-diaminopropane

6/2005Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53.
4/2003The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase.
4/2003Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity.
3/2002Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pierre Hainaut Research Topics

Disease

99Neoplasms (Cancer)
03/2022 - 01/2002
32Hepatocellular Carcinoma (Hepatoma)
02/2018 - 05/2003
19Lung Neoplasms (Lung Cancer)
01/2016 - 10/2002
14Infections
06/2012 - 06/2004
11Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2018 - 06/2007
9Liver Diseases (Liver Disease)
10/2019 - 06/2008
8Adenocarcinoma
03/2014 - 09/2002
8Carcinogenesis
01/2013 - 12/2006
7Chronic Hepatitis B
10/2019 - 02/2005
6Breast Neoplasms (Breast Cancer)
11/2015 - 01/2011
6Carcinoma (Carcinomatosis)
11/2014 - 10/2003
6Hepatitis B
11/2011 - 09/2005
5Fibrosis (Cirrhosis)
02/2018 - 11/2008
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2014 - 08/2005
5Persistent Infection
01/2012 - 09/2005
4Esophageal Squamous Cell Carcinoma
05/2021 - 09/2007
4Liver Neoplasms (Liver Cancer)
01/2019 - 12/2009
4Liver Cirrhosis (Hepatic Cirrhosis)
04/2015 - 11/2008
4Virus Diseases (Viral Diseases)
01/2011 - 06/2002
3Hepatitis C
10/2019 - 01/2011
3Hepatitis
10/2019 - 11/2008
3Alcoholism (Alcohol Abuse)
10/2019 - 01/2011
3Inflammation (Inflammations)
11/2017 - 04/2008
3Li-Fraumeni Syndrome
01/2017 - 01/2010
2Circulating Neoplastic Cells
02/2022 - 01/2017
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
02/2020 - 11/2017
2Melanoma (Melanoma, Malignant)
01/2017 - 01/2011
2Pancreatic Neoplasms (Pancreatic Cancer)
04/2016 - 10/2014
2Leukemia
01/2016 - 09/2004
2Obesity
11/2015 - 12/2010
2Adenocarcinoma of Lung
03/2014 - 12/2012
2Sarcoma (Soft Tissue Sarcoma)
03/2012 - 06/2010
2Metaplasia
10/2011 - 07/2007
2Neoplasm Metastasis (Metastasis)
10/2011 - 06/2010
2Endometrial Neoplasms (Endometrial Cancer)
10/2011 - 12/2010
2Coinfection
01/2011 - 01/2011
2Esophageal Neoplasms (Esophageal Cancer)
07/2007 - 03/2002
1COVID-19
01/2021
1Non-alcoholic Fatty Liver Disease
10/2019
1Paralysis (Palsy)
01/2019
1Intestinal Pseudo-Obstruction (Intestinal Pseudoobstruction)
01/2019
1Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2017

Drug/Important Bio-Agent (IBA)

36DNA (Deoxyribonucleic Acid)IBA
05/2021 - 01/2003
26Proteins (Proteins, Gene)FDA Link
01/2021 - 05/2003
24Biomarkers (Surrogate Marker)IBA
02/2022 - 05/2005
18AflatoxinsIBA
10/2019 - 05/2003
18Codon (Codons)IBA
04/2013 - 10/2002
11Biological ProductsIBA
11/2017 - 01/2003
8CarcinogensIBA
01/2011 - 06/2002
7Cell-Free Nucleic AcidsIBA
05/2021 - 05/2007
7Messenger RNA (mRNA)IBA
11/2014 - 01/2005
7Aflatoxin B1 (Aflatoxin B)IBA
06/2012 - 01/2004
5SmokeIBA
01/2009 - 10/2002
4Protein Isoforms (Isoforms)IBA
02/2020 - 01/2005
4Cisplatin (Platino)FDA LinkGeneric
01/2016 - 01/2007
4ErbB Receptors (EGF Receptor)IBA
12/2012 - 06/2007
4Cyclooxygenase 2 (Cyclooxygenase-2)IBA
10/2011 - 07/2007
4Hepatitis B Surface Antigens (HBsAg)FDA Link
02/2011 - 08/2007
4N-(2-mercaptoethyl)-1,3-diaminopropaneIBA
06/2005 - 03/2002
3RNA (Ribonucleic Acid)IBA
01/2018 - 04/2007
3OsteopontinIBA
09/2016 - 02/2012
3Formaldehyde (Formol)FDA Link
03/2014 - 07/2009
3Tumor Suppressor Protein p14ARF (p14ARF)IBA
03/2014 - 06/2007
3MutagensIBA
04/2013 - 01/2004
3Transcription Factors (Transcription Factor)IBA
12/2012 - 09/2007
3Hormones (Hormone)IBA
10/2011 - 02/2006
3Tumor Suppressor Protein p53IBA
09/2011 - 07/2004
3Estrogens (Estrogen)FDA Link
04/2011 - 01/2011
3Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
04/2011 - 04/2008
3Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA
09/2010 - 05/2003
3VaccinesIBA
12/2009 - 08/2007
2ChromatinIBA
03/2022 - 11/2014
2Tumor Biomarkers (Tumor Markers)IBA
02/2022 - 01/2009
2Circulating Tumor DNAIBA
02/2022 - 01/2017
2C-Reactive ProteinIBA
11/2017 - 12/2010
2CytokinesIBA
11/2017 - 12/2010
2Carrier Proteins (Binding Protein)IBA
01/2015 - 01/2009
22,2- bis(hydroxymethyl)- 1- azabicyclo(2,2,2,)octan- 3- oneIBA
10/2014 - 07/2008
2ParaffinIBA
03/2014 - 11/2010
2PhosphoproteinsIBA
12/2012 - 02/2002
2Paclitaxel (Taxol)FDA LinkGeneric
05/2012 - 06/2009
23-nitrotyrosineIBA
10/2011 - 04/2008
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2011 - 06/2007
2AcidsIBA
07/2007 - 01/2002
1EnzymesIBA
01/2022
1GoldIBA
04/2020
1aristolochic acid I (aristolochic acid)IBA
10/2019
1Phosphotransferases (Kinase)IBA
01/2019
1Sorafenib (BAY 43-9006)FDA Link
02/2018
1MiransertibIBA
02/2018
1Diethylnitrosamine (N-Nitrosodiethylamine)IBA
02/2018
1CrizotinibIBA
01/2018
15'- O- (9- phenylxanthen- 9- yl)- 2'- deoxynebularineIBA
01/2017
1fibulinIBA
01/2017

Therapy/Procedure

17Therapeutics
10/2019 - 01/2004
8Drug Therapy (Chemotherapy)
01/2022 - 06/2005
4Adjuvant Chemotherapy
06/2017 - 11/2010
1Radiotherapy
04/2020
1Catheters
10/2019
1Semiconductors
01/2017